Alcon logged a -1.7% change during today's afternoon session, and is now trading at a price of $87.78 per share.
Over the last year, Alcon logged a -0.2% change, with its stock price reaching a high of $101.1 and a low of $80.48. Over the same period, the stock underperformed the S&P 500 index by -12.0%. AThe company's 50-day average price was $89.82. Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. Based in Geneva, Switzerland, the Large-Cap Health Care company has 25,000 full time employees. Alcon has offered a 0.3% dividend yield over the last 12 months.
Generally Positive Cash Flows but Similar Gross Margins to the Industry Average of 56.33%:
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue (M) | $7,508 | $6,833 | $8,291 | $8,717 | $9,455 | $9,911 |
| Gross Margins | 49% | 43% | 56% | 54% | 55% | 56% |
| Net Margins | -10% | -8% | 4% | 5% | 10% | 10% |
| Net Income (M) | -$717 | -$533 | $344 | $439 | $964 | $952 |
| Net Interest Expense (M) | -$113 | -$124 | -$120 | -$134 | -$189 | -$192 |
| Depreciation & Amort. (M) | $1,456 | $1,626 | $1,220 | $1,111 | $1,226 | $1,226 |
| Diluted Shares (M) | 488 | 489 | 493 | 494 | 496 | 498 |
| Earnings Per Share | -$1.34 | -$1.09 | $0.76 | $0.68 | $1.96 | $2.05 |
| EPS Growth | n/a | 18.66% | 169.72% | -10.53% | 188.24% | 4.59% |
| Free Cash Flow (M) | $920 | $823 | $1,345 | $1,217 | $1,388 | $2,077 |
| Total Debt (M) | $3,218 | $3,949 | $3,966 | $4,541 | $4,676 | $4,538 |
| Net Debt / EBITDA | 1.89 | 2.09 | 1.33 | 2.0 | 1.58 | 1.08 |
| Current Ratio | 1.84 | 2.21 | 2.18 | 1.9 | 2.35 | 2.77 |
Alcon has generally positive cash flows and an excellent current ratio of 2.77. Additionally, the company's financial statements display a strong EPS growth trend and healthy leverage levels. Furthermore, Alcon has similar gross margins to its peers.
a Lower P/B Ratio Than Its Sector Average but Trading Above Its Fair Price:
Alcon has a trailing twelve month P/E ratio of 39.9, compared to an average of 22.94 for the Health Care sector. Based on its EPS guidance of $3.52, the company has a forward P/E ratio of 25.5. Alcon's PEG ratio is 2.9 on the basis of the 13.7% weighted average of the company and the broader market's EPS compound average growth rates. This suggests that the company's shares are overvalued. In contrast, the market is likely undervaluing Alcon in terms of its equity because its P/B ratio is 1.98 while the sector average is 3.19. The company's shares are currently trading 96.4% below their Graham number.
Alcon Has an Average Rating of Buy:
The 15 analysts following Alcon have set target prices ranging from $86.0 to $123.0 per share, for an average of $105.79 with a buy rating. The company is trading -17.0% away from its average target price, indicating that there is an analyst consensus of some upside potential.
The largest shareholder is Vanguard Group Inc, whose 4% stake in the company is worth $1,762,648,358.
